Picture

Northwestern Medicine
​Breakthroughs for Physicians

​​
  • Home
  • Specialties
    • Cardiovascular >
      • Research
      • Clinical Breakthroughs
      • News
    • Endocrinology >
      • Clinical Breakthroughs In Endocrinology
      • Research In Endocrinology
      • News
    • ENT (Otolaryngology) >
      • Clinical Breakthroughs
      • Research
      • News
    • Gastroenterology >
      • Clinical Breakthroughs
      • Research
      • News
    • Geriatrics >
      • Clinical Breakthroughs
      • Research
      • News
    • Neurosciences >
      • Rare and Complex Brain Tumors
      • Research
      • COVID-19 and Neurosciences
      • News
      • Clinical Breakthroughs
    • OB-GYN >
      • Clinical Breakthroughs
      • Research
      • News
    • Oncology >
      • Clinical Breakthroughs
      • Research
      • News
    • Ophthalmology >
      • Clinical Breakthroughs
      • Research
      • News
    • Organ Transplant >
      • Clinical Breakthroughs
      • Research
      • News
    • Orthopaedics >
      • Clinical Breakthroughs
      • Research
      • News
    • Psychiatry >
      • Clinical Breakthroughs
      • Research
      • News
    • Pulmonary >
      • Clinical Breakthroughs
      • Research
      • News
    • Rehabilitation >
      • Clinical Breakthroughs
      • News
    • Rheumatology >
      • Clinical Breakthroughs
      • Research
      • News
    • Urology >
      • Clinical Breakthroughs
      • Research
      • News
  • CME
  • REFERRALS
    • Refer to NM Cardiovascular
    • Refer to NM Neurosciences
    • Refer to Other Specialties

< BACK TO RESEARCH IN ONCOLOGY

August 2022

ONCOLOGY

EMERGING THERAPY FOR RELAPSED B-CELL LYMPHOMA

Featuring: Leo Gordon, MD

​
​An emerging therapy showed promise in patients with relapsed B-cell lymphoma who are not good candidates for stem cell transplants, according to a non-randomized phase II trial published in The Lancet Oncology.

The therapy, which genetically modifies patient T-cells into aggressive cancer killers, could provide a new treatment option for these patients, according to Leo Gordon, MD, the Abby and John Friend Professor of Oncology Research, professor of Medicine in the Division of Hematology and Oncology and senior author of the study.

“We need to find other options for these patients, who are not ideal candidates for stem cell transplants,” said Gordon, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

B-cells are blood cells that make antibodies to fight bacteria and viruses. In B-cell lymphoma, the body produces too many abnormal B-cells which can spread to other parts of the body such as the lymph nodes, bone marrow or spleen.

For patients whose lymphoma is treated and then relapses, the preferred treatment is a bone marrow transplant, a procedure that infuses healthy blood-forming stem cells into bone marrow to replace those that have been damaged by cancer or chemotherapy. However, the transplant poses significant risks, so many patients are not good candidates due to age or comprised cardiac or renal function, according to Gordon.

“If they’re not a good candidate for a transplant, then the treatment goals are more palliative than they are curative, until now” Gordon said.

Chimeric antigen receptor (CAR-T) treatments are a possible solution to this problem. Clinicians collect T-cells from patients in a procedure called leukapheresis, which involves removing T-cells from the blood, then sending the cells are to a laboratory where new genes are inserted into those cells.

The genes cause the T-cells to recognize and attack a target — in this case, a particular protein on lymphoma cells. This process of manufacturing the cells can take several weeks, and afterwards, the cells are infused back into the patient.

In the trial, investigators recruited more than 70 patients with relapsed B-cell lymphoma who, by age and comorbidity criteria, were not good candidates for a transplant. Sixty-one patients ultimately received the treatment, and 80 percent responded to the treatment. A little more than half of the 61 patients experienced complete remission of cancer, with a median remission duration of nearly 22 months.
Side-effects were present but in line with previous studies examining CAR-T therapy, with about 40 percent of patients experiencing some immune system complications but no deaths.

The results are promising, Gordon said, but there are additional questions to ask about CAR-T in patients in B-cell lymphoma. In the future, Gordon said he wants to examine usage of CAR-T therapy earlier in disease.

“We see many high-risk patients where we don’t expect a complete response from chemotherapy — can CAR-T be used here to produce better outcomes?” Gordon said.
This study was funded by Juno Therapeutics, a Bristol-Myers Squibb company.


This article was originally published in the Feinberg School of Medicine News Center on August 12, 2022.
Lee Cooper, PhD headshot
Leo Gordon, MD, the Abby and John Friend Professor of Oncology Research, professor of Medicine in the Division of Hematology and Oncology, was senior author of a study published in The Lancet Oncology.

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​
Call 844.344.6663
Find an NM ONCOLOGIST

You May Also Like

B-Cell Acute Illustration

February 2021

ONCOLOGY
Identifying Therapeutic Targets for B-cell Acute Lymphoblastic Leukemia
Image of Lurie Cancer Center Building

September 2021

ONCOLOGY
Lurie Cancer Center Receives Prostate Cancer SPORE from the NCI
Epigenetic Markers Illustration

December 2020

ONCOLOGY
Identifying Oncogenes through Epigenetic Markers

Northwestern Medicine Breakthroughs for Physicians

About Us     Terms of Use     Privacy Policy     How to Vote for U.S. News & World Report Best Hospitals
© 2025 Northwestern Medicine® and Northwestern Memorial HealthCare. 
Northwestern Medicine® is a trademark of Northwestern Memorial HealthCare, used by Northwestern University
Connect with us
[email protected]
International physicians, contact [email protected]
  • Home
  • Specialties
    • Cardiovascular >
      • Research
      • Clinical Breakthroughs
      • News
    • Endocrinology >
      • Clinical Breakthroughs In Endocrinology
      • Research In Endocrinology
      • News
    • ENT (Otolaryngology) >
      • Clinical Breakthroughs
      • Research
      • News
    • Gastroenterology >
      • Clinical Breakthroughs
      • Research
      • News
    • Geriatrics >
      • Clinical Breakthroughs
      • Research
      • News
    • Neurosciences >
      • Rare and Complex Brain Tumors
      • Research
      • COVID-19 and Neurosciences
      • News
      • Clinical Breakthroughs
    • OB-GYN >
      • Clinical Breakthroughs
      • Research
      • News
    • Oncology >
      • Clinical Breakthroughs
      • Research
      • News
    • Ophthalmology >
      • Clinical Breakthroughs
      • Research
      • News
    • Organ Transplant >
      • Clinical Breakthroughs
      • Research
      • News
    • Orthopaedics >
      • Clinical Breakthroughs
      • Research
      • News
    • Psychiatry >
      • Clinical Breakthroughs
      • Research
      • News
    • Pulmonary >
      • Clinical Breakthroughs
      • Research
      • News
    • Rehabilitation >
      • Clinical Breakthroughs
      • News
    • Rheumatology >
      • Clinical Breakthroughs
      • Research
      • News
    • Urology >
      • Clinical Breakthroughs
      • Research
      • News
  • CME
  • REFERRALS
    • Refer to NM Cardiovascular
    • Refer to NM Neurosciences
    • Refer to Other Specialties